rhodamine b has been researched along with Ovarian Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Csuk, R; Heise, NV; Hoenke, S; Kozubek, M; Major, D; Serbian, I | 1 |
| Chen, L; Di, W; Liu, T; Qiu, L; Wang, X; Wang, Y; Zhou, J | 1 |
2 other study(ies) available for rhodamine b and Ovarian Neoplasms
| Article | Year |
|---|---|
Rhodamine 101 Conjugates of Triterpenoic Amides Are of Comparable Cytotoxicity as Their Rhodamine B Analogs.
Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Ovarian Neoplasms; Rhodamines; Structure-Activity Relationship; Triterpenes | 2022 |
Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Topics: Alginates; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Delayed-Action Preparations; Drug Delivery Systems; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Female; Glucuronic Acid; Hexuronic Acids; Humans; Kinetics; Liposomes; Mice; Mice, Nude; Nanoparticles; Ovarian Neoplasms; Polyethylene Glycols; Rhodamines; Spheroids, Cellular | 2014 |